Ethylene oxide (EO) sterilization is indispensable for heat- and moisture-sensitive medical devices, yet it leaves toxic residues that can migrate into patients during clinical use. In-vivo residual ethylene oxide assessment quantifies EO and its by-products—ethylene chlorohydrin (ECH) and ethylene glycol (EG)—and evaluates the dose actually delivered to the patient against the tolerable exposure limits defined in ISO 10993-7. This article explains the regulatory framework, sample types, testing items, analytical methods, and practical applications of a compliant EO residual evaluation program.
Technical Overview
Ethylene oxide sterilization, validated in accordance with ISO 11135, remains one of the most widely used terminal sterilization processes for medical devices that cannot withstand steam or dry heat. Although highly effective against microorganisms, EO is a reactive alkylating agent classified as an irritant, mutagen, and probable human carcinogen. During sterilization, residues of EO can be absorbed by polymeric materials, adhesives, and cellulose-based components, and EO can also react with chloride-containing materials such as PVC to form ethylene chlorohydrin (ECH, 2-chloroethanol) and with water to form ethylene glycol (EG). These residues can desorb from the device after implantation or clinical contact and constitute a direct chemical hazard to the patient.
In-vivo residual EO assessment therefore focuses not merely on how much EO remains inside a device, but on how much residue can be delivered to a patient under realistic worst-case clinical use. ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals) provides the internationally recognized framework for this evaluation, and it is adopted in China as GB/T 16886.7. For infusion, transfusion, and injection equipment, GB/T 14233.1 further specifies the headspace gas chromatographic determination of EO residuals. The evaluation classifies devices by patient contact duration and assigns corresponding tolerable exposure (TE) limits:
- Limited exposure devices (contact up to 24 hours): tolerable exposure of 4 mg for EO and 9 mg for ECH per device.
- Prolonged exposure devices (contact from 24 hours to 30 days): tolerable exposure of 2 mg/day for EO and 3.5 mg/day for ECH.
- Persistent exposure devices (contact exceeding 30 days): tolerable exposure of 0.1 mg/day for EO and 0.4 mg/day for ECH.
The magnitude of residuals depends on material type and mass, device geometry, packaging permeability, load configuration, and—critically—the aeration (degassing) time and temperature after sterilization. Consequently, residual assessment is closely linked to sterilization cycle design, aeration validation, and product release specifications, and it forms an integral part of the biological evaluation plan required by ISO 10993-1 and of chemical risk management under ISO 10993-17.
Testing Samples
EO-Sterilized Single-Use Clinical Devices
Typical samples include syringes, hypodermic needles, intravenous catheters, infusion and transfusion sets, hemodialyzers, extracorporeal blood circuits, oxygenators, anesthesia breathing circuits, urinary catheters, wound dressings, surgical drapes and gowns, and minimally invasive access devices. These devices usually fall into the limited or prolonged exposure categories, and sampling is performed on finished, sterilized, packaged product drawn from routine production batches.
Implantable and Persistent-Contact Devices
Intraocular lenses, hernia meshes, absorbable scaffolds, tissue repair patches, orthopedic implants with polymeric components, implantable drug-delivery components, and pacing system accessories represent the most demanding cases. Because patient contact exceeds 30 days, the persistent-exposure limits apply, and evaluation typically requires exhaustive extraction combined with worst-case dose modeling to demonstrate compliance.
Fluid-Path and Combination Products
Devices in which EO or ECH residues may leach into infused or recirculated fluids—administration sets, in-line filters, stopcocks, extension tubing, and cardiopulmonary bypass components—require simulated-use extraction in which extraction fluid is passed through or contacted with the fluid path under clinically representative conditions to capture the delivered dose.
Aeration Profiling and Shelf-Life Study Samples
Residual levels decline continuously during aeration and storage. Samples are therefore collected at defined time points after sterilization (for example, at intermediate aeration intervals and at the intended product release point) to construct residual decline curves, support aeration cycle definition, and demonstrate that the device remains within limits at the moment of release.
Sample Handling and Logistics
Because EO is volatile and ECH is water soluble and mobile, improper handling can bias results. Samples must be retained in their original sterilization packaging, transported under controlled conditions, protected from heat and physical damage, and delivered promptly to accredited third-party laboratories with a documented chain of custody.
Testing Items
A complete in-vivo residual EO assessment generally encompasses the following determinations, each reported on a per-device basis (mg/device) or per unit mass basis (micrograms per gram) as appropriate:
- Residual ethylene oxide (EO) content in the finished device.
- Residual ethylene chlorohydrin (ECH) content, mandatory whenever chloride-containing materials or chloride-bearing fluids are involved.
- Residual ethylene glycol (EG), evaluated as a supporting item where justified by material composition and contact scenario.
- Simulated-use extraction study: concentration of EO and ECH in the extraction medium and the resulting patient-delivered dose per day of contact.
- Exhaustive extraction study: total extractable residual burden used to establish worst-case margins for prolonged and persistent exposure devices.
- Aeration decline profile: residual levels as a function of post-sterilization holding time to define the minimum aeration period.
- Compliance statement comparing the delivered dose with the ISO 10993-7 tolerable exposure limits for the applicable contact-duration category.
Testing Methods
Sample Preparation and Extraction
ISO 10993-7 defines two complementary extraction concepts. Simulated-use extraction replicates clinical contact as closely as reasonably possible—for example, water or an aqueous medium held at approximately 37 degrees Celsius for a duration matching the intended patient contact—to estimate the actual delivered dose. Exhaustive extraction applies repeated extraction cycles until the residue recovered in a subsequent cycle is negligible, providing the total residual inventory for conservative risk assessment of long-contact devices. The extraction fluid, temperature, surface-to-volume ratio, and cut-off criteria are selected and justified in the test protocol.
Headspace Gas Chromatography for EO
EO is quantified by static headspace gas chromatography with flame ionization detection (GC-FID), following the reference methods of ISO 10993-7 and, for infusion and injection devices, GB/T 14233.1. Sealed headspace vials are thermostatted to establish equilibrium partitioning of EO between the sample matrix and the gas phase, and quantification is performed against multi-point calibration curves prepared from traceable EO standards. This approach offers high sensitivity, minimal sample manipulation, and excellent suitability for volatile analytes.
Determination of ECH by GC-FID and GC-MS
ECH is a polar, semi-volatile compound and is typically determined from the aqueous extract by gas chromatography with flame ionization detection or, for enhanced selectivity and confirmatory identification, gas chromatography coupled with mass spectrometry (GC-MS). Where matrix interferences occur, derivatization or optimized chromatographic conditions are employed. Method detection limits are established to demonstrate compliance well below the applicable tolerable exposure limits.
Method Validation and Data Evaluation
Regardless of the instrumental technique, the analytical method is validated for linearity, accuracy and recovery, precision (repeatability and reproducibility), limits of detection and quantification, and robustness in the specific device matrix. The final report converts measured extract concentrations into a per-device delivered dose, compares this dose with the tolerable exposure for the relevant exposure category, and states the safety margin. Any exceedance triggers aeration extension, packaging redesign, or cycle re-optimization before release.
Applications
In-vivo residual EO assessment supports multiple stages of the medical device lifecycle:
- Regulatory submissions: demonstrating conformity with ISO 10993-7 or GB/T 16886.7 as part of premarket biological evaluation documentation for national registration files.
- Sterilization and aeration optimization: defining minimum aeration time and temperature during ISO 11135 process validation so that residual levels fall below limits at the designated release point.
- Product release and periodic verification: establishing acceptance criteria and supporting routine or periodic testing of production batches.
- Change control: re-evaluating residuals after changes to materials, suppliers, packaging configuration, sterilization load, or cycle parameters.
- Risk management: integrating residual data into the biological evaluation plan per ISO 10993-1 and the chemical toxicity risk assessment per ISO 10993-17 within the overall ISO 14971 risk management file.
- Shelf-life substantiation: confirming that residual compliance is maintained at product release throughout the claimed storage period.
FAQ
Why is the assessment described as "in-vivo" when it is performed in a laboratory?
The term emphasizes that the decisive endpoint is the dose of EO and ECH delivered to the patient during actual clinical use, not simply the total residual retained in the device. Simulated-use extraction under physiological conditions provides the best laboratory estimate of this in-vivo delivered dose and is the basis for comparison with ISO 10993-7 limits.
Why must ECH be measured in addition to EO?
ECH is a reaction product of EO with chloride ions, commonly formed in PVC and other chlorine-containing materials or in contact with chloride-bearing fluids. ECH is itself systemically toxic, and ISO 10993-7 assigns it independent tolerable exposure limits, so a device can pass the EO criterion yet fail on ECH.
When should simulated-use extraction be used instead of exhaustive extraction?
Simulated-use extraction is preferred for estimating realistic patient exposure, particularly for limited-exposure devices and fluid-path products. Exhaustive extraction provides a deliberately conservative total residual burden and is generally applied to prolonged- and persistent-exposure devices or when simulated-use conditions cannot be defined with confidence.
Can residual testing ever be waived?
Yes, in justified cases. If a device is not EO sterilized, if no EO-reactive materials are present, or if robust existing data on identical materials, geometry, and cycle demonstrate ample margins, a documented scientific rationale in the biological evaluation plan may support reduced or bracketed testing in lieu of full retesting.
When should samples be taken relative to sterilization?
The critical measurement point is the earliest allowed product release, that is, the end of the qualified aeration period, because residuals are highest at that moment. Testing at this point guarantees that any device shipped to clinicians complies with the applicable limits throughout its shelf life.
How are the results finally judged?
The calculated delivered dose per device, or per day of contact, is compared with the tolerable exposure for the applicable contact-duration category. A passing result with an adequate safety margin supports biological safety; results approaching or exceeding limits require cycle modification, extended aeration, or design intervention before the device can be released.